COMPARE · Data as of August 21, 2026
ALC vs STVN
Verdict: Side-by-side breakdown using the Bull Rankings model. ALC scored 73.3, STVN scored 63.4 — ALC leads.
Compare another set
ALC
Alcon Inc.
73.3
$73.63 · $35.6B
Score gap
9.9
ALC leads
STVN
Stevanato Group S.p.A.
63.4
$22.60 · $6.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthALC+10.5%
- Strongest balance sheetALC0.25
- Highest qualityALC87 / 100
- Largest discount to fair valueALC-30%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ALC
stronger →← stronger
STVN
87
Qualityreturns · margins · balance sheet
52
71
Growthrevenue & earnings expansion
75
63
Valuevaluation vs sector peers
76
STVN is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALC
STVN
$2.1bB
FCF
-$36mF
+10.5%B
Rev
+7.4%B
0.25B
D/E
0.29B
56.2xC
P/E
—
1.53C+
PEG
0.37A
—
P/S
4.3xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALC
STVN
30% below
Price vs fair valuelower is cheaper
—
~0%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+24%
1-yr DCF upside
—
+43%
5-yr DCF upside
—
+76%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALC
Why this score
- Durable high returns
STVN
Why this score
- Foreign reporter (EUR)
The companies
ALCAlcon Inc.
Why now
Medical Instruments & Supplies · market cap $35.6b. 16% off the 52-week high of $87.64. Revenue growing +10%, comfortably above the S&P median. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $85.24 (implying +16% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 30% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Trailing P/E 56.2x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating.
STVNStevanato Group S.p.A.
Why now
Medical Instruments & Supplies · market cap $6.2b. 19% off the 52-week high of $28.00. PEG 0.37 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $24.83 (implying +10% upside).
Moat
Higher-variance name — the moat signals on the quantitative card are modest, so the durability case rests on execution (turning current growth into durable earnings power) or an un-monetized asset (IP / network effects / first-mover position) rather than an entrenched competitive position.
Risk
Free cash flow is negative (-$36m) — capital raises or debt issuance likely required; dilution / leverage risk. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALC and STVN diverge
On the headline score the gap is 9.9 points in favor of ALC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityALC 87.5 · STVN 52.1ALC +35.4
- ValueALC 63.2 · STVN 75.6STVN +12.4
- GrowthALC 71.4 · STVN 75.4STVN +4.0
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.